Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Cancer Letters
|
August 16, 2025
Single-cell profiling identifies biomarkers for immunochemotherapy in esophageal squamous cell carcinoma
Changchun Wang, Guanglei Xie, Mingming Jia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Ying Jin, Yamei Chen, Huarong Tang, et al.
The Lancet. Respiratory Medicine
|
November 24, 2024
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
Dongsheng Yue, Wenxiang Wang, Hongxu Liu, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
February 28, 2026
Pathologic complete response after neoadjuvant immunochemotherapy: persistent recurrence risk highlights the need for stratified management
Chang Yuan, Chunji Chen, Zhichao Liu, et al.
Translational Lung Cancer Research
|
February 10, 2023
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)
Chong-Rui Xu, Qixun Chen, Chengzhi Zhou, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
January 25, 2026
Association of immune-related adverse events with survival outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a national multicenter retrospective cohort study in China
Chunji Chen, Chang Yuan, Zhichao Liu, et al.
Frontiers in Oncology
|
August 19, 2022
A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
Hong Yang, Lin Wang, Guoliang Shao, et al.
Nature Medicine
|
July 2, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Jianjun Qin, Liyan Xue, Anlin Hao, et al.
Translational Lung Cancer Research
|
January 25, 2021
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Wenhua Liang, Kaican Cai, Chun Chen, et al.
JAMA
|
January 16, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial
Shun Lu, Wei Zhang, Lin Wu, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Cancer Letters
|
August 16, 2025
Single-cell profiling identifies biomarkers for immunochemotherapy in esophageal squamous cell carcinoma
Changchun Wang, Guanglei Xie, Mingming Jia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Ying Jin, Yamei Chen, Huarong Tang, et al.
The Lancet. Respiratory Medicine
|
November 24, 2024
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
Dongsheng Yue, Wenxiang Wang, Hongxu Liu, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
February 28, 2026
Pathologic complete response after neoadjuvant immunochemotherapy: persistent recurrence risk highlights the need for stratified management
Chang Yuan, Chunji Chen, Zhichao Liu, et al.
Translational Lung Cancer Research
|
February 10, 2023
Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)
Chong-Rui Xu, Qixun Chen, Chengzhi Zhou, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
January 25, 2026
Association of immune-related adverse events with survival outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a national multicenter retrospective cohort study in China
Chunji Chen, Chang Yuan, Zhichao Liu, et al.
Frontiers in Oncology
|
August 19, 2022
A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
Hong Yang, Lin Wang, Guoliang Shao, et al.
Nature Medicine
|
July 2, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Jianjun Qin, Liyan Xue, Anlin Hao, et al.
Translational Lung Cancer Research
|
January 25, 2021
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Wenhua Liang, Kaican Cai, Chun Chen, et al.
JAMA
|
January 16, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial
Shun Lu, Wei Zhang, Lin Wu, et al.
Page
of 9